Skip to Main content Skip to Navigation
Journal articles

Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement

Abstract : The ideal treatment for multiple sclerosis (MS) would target both the neuroinflammatory component of the disease (peripheral and central) and its neurodegenerative component, via modulation of a ubiquitous and pleiotropic common target. Sphingosine-1-phosphate (S1P), a product of sphingosine metabolism, regulates many biological functions (including cell proliferation and survival, cell migration, the immune response and cardiovascular function) via five subtypes of receptor. These receptors are expressed in all types of brain cells where they modulate a number of processes involved in neuronal plasticity, including myelination, neurogenesis and neuroprotection. This profile has aroused interest in modulation of S1P function as a therapeutic target in many brain diseases, particularly those in which the immune system plays a role in the development of brain lesions. Fingolimod, a S1P receptor modulator, exerts its beneficial effects in MS through its anti-inflammatory and anti-neurodegenerative effects. This review discusses recent evidence indicating that fingolimod may target both the inflammatory and neurodegenerative components of the disease process in MS.
Document type :
Journal articles
Complete list of metadata
Contributor : Sylvie Le Bihan Connect in order to contact the contributor
Submitted on : Wednesday, January 29, 2020 - 3:14:25 PM
Last modification on : Thursday, May 19, 2022 - 2:56:02 PM



Regis Bordet, William Camu, Jérôme de Sèze, David-Axel Laplaud, Jean-Christophe Ouallet, et al.. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique, Elsevier Masson, 2019, Epub ahead of print. ⟨10.1016/j.neurol.2019.02.007⟩. ⟨inserm-02459649⟩



Record views